FAQ/Help |
Calendar |
Search |
Today's Posts |
01-09-2013, 10:02 AM | #1 | ||
|
|||
Magnate
|
great to be a rodent with PD!
http://pharmalive.com/News/Index.cfm?articleid=873768 |
||
Reply With Quote |
"Thanks for this!" says: | sim00 (01-12-2013) |
01-10-2013, 11:46 PM | #2 | ||
|
|||
Junior Member
|
Dr. Rubinfield, cofounder of AMGEN added to corporate advisory board of Amarantus and stated this:
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.” Imo, this is a huge endorsement for Amarantus and one to keep a close eye on... |
||
Reply With Quote |
"Thanks for this!" says: | sim00 (01-12-2013) |
01-19-2013, 12:55 PM | #3 | |||
|
||||
Member
|
MANF publication
The endoplasmic reticulum (ER) is the part of the cell where unfolded proteins are properly folded and then exported into different parts of the cell, or secreted out of the cell, so that they can perform their normal biological functions. When the ER becomes stressed, protein folding is compromised, and cells can become dysfunctional. Apoptosis, also known as Programmed Cell Death, is one of the main side effects of protein misfolding due to ER stress, and several independent peer-reviewed research papers have demonstrated that MANF plays a critical role in reducing protein misfolding and apoptosis. MANF has been shown to be upregulated inside the cell, and subsequently secreted out of the cell, with data demonstrating that MANF ultimately reduces apoptosis in the cells in which it originates, the cells it interacts with once secreted out of the cell, as well as when manufactured MANF is administered to various parts of the body undergoing ER stress. Amarantus is seeking to administer manufactured MANF to areas in the body where ER-stress occurs due to injury or disease, giving the body additional quantities of MANF during times of stress in order to reduce apoptosis and improve cellular function. The Company believes that if cellular function can be improved, overall system recovery is likely in many therapeutic indications. ER-stress and protein misfolding appear to be a key component of Parkinson's disease biology. Amarantus' Chief Scientist originally discovered MANF, and the Company was awarded composition of matter patents on MANF in Europe in 2010 and in the United States in 2011. The Company also recently won a court challenge to its composition of matter patents in Europe. The Company also owns worldwide patent applications covering various methods of using MANF as it relates to neurological conditions.
__________________
VictoriaLou . |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neuroresto | Parkinson's Disease | |||
BrainStorm Announces Clinical Data Supporting Safety and Efficacy of NurOwn™... (ALS) | Parkinson's Disease | |||
RXi Data Shows Long-Term CNS Delivery of | ALS News & Research | |||
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for | ALS News & Research | |||
Safinamide..Merck Serono Announces 18-Month Safety and Efficacy Data Phase III Trial | Parkinson's Disease Clinical Trials |